Integrating genomics onto clinical pediatric oncology using the molecular tumor board at the Memorial Sloan Kettering Cancer Center Journal Article


Authors: Ortiz, M. V.; Kobos, R.; Walsh, M.; Slotkin, E. K.; Roberts, S.; Berger, M. F.; Hameed, M.; Solit, D.; Ladanyi, M.; Shukla, N.; Kentsis, A.
Article Title: Integrating genomics onto clinical pediatric oncology using the molecular tumor board at the Memorial Sloan Kettering Cancer Center
Abstract: Background: Pediatric oncologists have begun to leverage tumor genetic profiling to match patients with targeted therapies. At the Memorial Sloan Kettering Cancer Center (MSKCC), we developed the Pediatric Molecular Tumor Board (PMTB) to track, integrate, and interpret clinical genomic profiling and potential targeted therapeutic recommendations. Procedure: This retrospective case series includes all patients reviewed by the MSKCC PMTB from July 2014 to June 2015. Cases were submitted by treating oncologists and potential treatment recommendations were based upon the modified guidelines of the Oxford Centre for Evidence-Based Medicine. Results: There were 41 presentations of 39 individual patients during the study period. Gliomas, acute myeloid leukemia, and neuroblastoma were the most commonly reviewed cases. Thirty nine (87%) of the 45 molecular sequencing profiles utilized hybrid-capture targeted genome sequencing. In 30 (73%) of the 41 presentations, the PMTB provided therapeutic recommendations, of which 19 (46%) were implemented. Twenty-one (70%) of the recommendations involved targeted therapies. Three (14%) targeted therapy recommendations had published evidence to support the proposed recommendations (evidence levels 1–2), eight (36%) recommendations had preclinical evidence (level 3), and 11 (50%) recommendations were based upon hypothetical biological rationales (level 4). Conclusions: The MSKCC PMTB enabled a clinically relevant interpretation of genomic profiling. Effective use of clinical genomics is anticipated to require new and improved tools to ascribe pathogenic significance and therapeutic actionability. The development of specific rule-driven clinical protocols will be needed for the incorporation and evaluation of genomic and molecular profiling in interventional prospective clinical trials. © 2016 Wiley Periodicals, Inc.
Keywords: molecular biology; pediatric oncology; new agents; cancer pharmacology
Journal Title: Pediatric Blood and Cancer
Volume: 63
Issue: 8
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Date Published: 2016-08-01
Start Page: 1368
End Page: 1374
Language: English
DOI: 10.1002/pbc.26002
PUBMED: 27082517
PROVIDER: scopus
PMCID: PMC5429592
DOI/URL:
Notes: Article -- Export Date: 2 August 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Meera Hameed
    284 Hameed
  2. David Solit
    781 Solit
  3. Marc Ladanyi
    1332 Ladanyi
  4. Michael Forman Berger
    768 Berger
  5. Rachel Kobos
    75 Kobos
  6. Neerav Shukla
    160 Shukla
  7. Emily Kanaya Slotkin
    65 Slotkin
  8. Stephen Stacy Roberts
    107 Roberts
  9. Alex   Kentsis
    104 Kentsis
  10. Michael Francis Walsh
    156 Walsh
  11. Michael Vincent Ortiz
    62 Ortiz